

# Gerhardt Attard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4699338/publications.pdf>

Version: 2024-02-01

220  
papers

25,631  
citations

10389

72  
h-index

6654

156  
g-index

227  
all docs

227  
docs citations

227  
times ranked

20980  
citing authors

#	ARTICLE	IF	CITATIONS
1	Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 825-836.	1.6	40
2	Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings. <i>European Journal of Cancer</i> , 2022, 160, 24-60.	2.8	12
3	Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 713-719.	3.9	17
4	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. <i>Lancet, The</i> , 2022, 399, 447-460.	13.7	173
5	The ReIMAGINE prostate cancer risk study protocol: A prospective cohort study in men with a suspicion of prostate cancer who are referred onto an MRI-based diagnostic pathway with donation of tissue, blood and urine for biomarker analyses.. <i>PLoS ONE</i> , 2022, 17, e0259672.	2.5	2
6	Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). <i>International Journal of Cancer</i> , 2022, 151, 422-434.	5.1	29
7	Cost-utility analysis of adding abiraterone acetate plus prednisone/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data. <i>PLoS ONE</i> , 2022, 17, e0269192.	2.5	4
8	Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. <i>PLoS Medicine</i> , 2022, 19, e1003998.	8.4	35
9	Blood-based liquid biopsies for prostate cancer: clinical opportunities and challenges. <i>British Journal of Cancer</i> , 2022, 127, 1394-1402.	6.4	25
10	ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. <i>Annals of Oncology</i> , 2022, 33, 750-768.	1.2	204
11	Circulating Androgen Receptor for Prognosis and Treatment Selection in Prostate Cancer. <i>European Urology Oncology</i> , 2021, 4, 740-744.	5.4	7
12	Validation of a 22-Gene Genomic Classifier in Patients With Recurrent Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 544.	7.1	82
13	Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer. <i>JAMA Oncology</i> , 2021, 7, 555.	7.1	66
14	CD38 in Advanced Prostate Cancers. <i>European Urology</i> , 2021, 79, 736-746.	1.9	21
15	Blood Biomarker Landscape in Patients with High-risk Nonmetastatic Castration-Resistant Prostate Cancer Treated with Apalutamide and Androgen-Deprivation Therapy as They Progress to Metastatic Disease. <i>Clinical Cancer Research</i> , 2021, 27, 4539-4548.	7.0	6
16	Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multicenter international trial. <i>Annals of Oncology</i> , 2021, 32, 726-735.	1.2	22
17	Circulating androgen receptor gene amplification and resistance to <sup>177</sup> Lu-PSMA-617 in metastatic castration-resistant prostate cancer: results of a Phase 2 trial. <i>British Journal of Cancer</i> , 2021, 125, 1226-1232.	6.4	13
18	Plasma androgen receptor and response to adapted and standard docetaxel regimen in castration-resistant prostate cancer: A multicenter biomarker study. <i>European Journal of Cancer</i> , 2021, 152, 49-59.	2.8	4

#	ARTICLE	IF	CITATIONS
19	589P Dynamics of peripheral blood immune profiling associated with tumour progression in metastatic castration resistant prostate cancer (mCRPC). <i>Annals of Oncology</i> , 2021, 32, S637-S638.	1.2	0
20	Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse. <i>Nature Communications</i> , 2021, 12, 5307.	12.8	58
21	584P Health-related quality of life (HRQoL) in ACIS: A phase III trial of apalutamide with abiraterone acetate and prednisone (APA + AAP) vs AAP in metastatic castration-resistant prostate cancer (mCRPC). <i>Annals of Oncology</i> , 2021, 32, S634.	1.2	0
22	Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. <i>Lancet Oncology</i> , The, 2021, 22, 1541-1559.	10.7	60
23	583P Baseline plasma tumour DNA (ptDNA) correlates with PSA kinetics in metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone or enzalutamide. <i>Annals of Oncology</i> , 2021, 32, S633.	1.2	0
24	LBA4 Abiraterone acetate plus prednisolone (AAP) with or without enzalutamide (ENZ) added to androgen deprivation therapy (ADT) compared to ADT alone for men with high-risk non-metastatic (M0) prostate cancer (PCa): Combined analysis from two comparisons in the STAMPEDE platform protocol. <i>Annals of Oncology</i> , 2021, 32, S1298.	1.2	7
25	Prostate Cancer Foundation Hormone-Sensitive Prostate Cancer Biomarker Working Group Meeting Summary. <i>Urology</i> , 2021, 155, 165-171.	1.0	11
26	650TiP PARADIGM: Plasma analysis for response assessment and to direct the management of metastatic prostate cancer (mPCa). <i>Annals of Oncology</i> , 2021, 32, S677.	1.2	0
27	Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHARTED trial. <i>Annals of Oncology</i> , 2021, 32, 1157-1166.	1.2	43
28	Should Patients with High-risk Localised or Locally Advanced Prostate Cancer Receive Abiraterone Acetate in Addition to Androgen Deprivation Therapy? Update on a Planned Analysis of the STAMPEDE Trial. <i>European Urology</i> , 2021, 80, 522-523.	1.9	5
29	Emerging Prognostic Groups Across the Spectrum of Metastatic Castration-Sensitive Prostate Cancer: Disease Outcomes and Genomics. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, e294-e295.	0.8	0
30	ABEMUS: platform-specific and data-informed detection of somatic SNVs in cfDNA. <i>Bioinformatics</i> , 2020, 36, 2665-2674.	4.1	7
31	Plasma tumour DNA as an early indicator of treatment response in metastatic castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2020, 123, 982-987.	6.4	22
32	Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial. <i>JCO Precision Oncology</i> , 2020, 4, 882-897.	3.0	22
33	692TiP BRCA2men: An international, multicentre, observational and ambispective study to validate the predictive value of germline BRCA2 mutations for selecting the first-line of treatment in metastatic castration-resistant prostate cancer (mCRPC). <i>Annals of Oncology</i> , 2020, 31, S547-S548.	1.2	2
34	634P Impact of metastatic lymph node burden on survival in patients with mHSPC from the "docetaxel comparison" of the STAMPEDE trial. <i>Annals of Oncology</i> , 2020, 31, S522-S523.	1.2	1
35	Pharmacokinetics, Safety, and Antitumor Effect of Apalutamide with Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer: Phase Ib Study. <i>Clinical Cancer Research</i> , 2020, 26, 3517-3524.	7.0	11
36	The Automated Bone Scan Index as a Predictor of Response to Prostate Radiotherapy in Men with Newly Diagnosed Metastatic Prostate Cancer: An Exploratory Analysis of STAMPEDEâ€™s â€œM1   RT Comparisonâ€•. <i>European Urology Oncology</i> , 2020, 3, 412-419.	5.4	9

#	ARTICLE	IF	CITATIONS
37	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020, 77, 508-547.	1.9	278
38	Genome-wide plasma DNA methylation features of metastatic prostate cancer. <i>Journal of Clinical Investigation</i> , 2020, 130, 1991-2000.	8.2	68
39	Identification of single nucleotide variants using position-specific error estimation in deep sequencing data. <i>BMC Medical Genomics</i> , 2019, 12, 115.	1.5	10
40	Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN. <i>Annals of Oncology</i> , 2019, 30, v347-v348.	1.2	6
41	Drivers and therapeutic vulnerabilities in AR indifferent anti-androgen resistant prostate cancer cells. <i>European Urology Supplements</i> , 2019, 18, e3104.	0.1	0
42	Abiraterone in "High" and "Low-risk" Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology</i> , 2019, 76, 719-728.	1.9	142
43	Drivers of AR indifferent anti-androgen resistance in prostate cancer cells. <i>Scientific Reports</i> , 2019, 9, 13786.	3.3	44
44	Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. <i>Annals of Oncology</i> , 2019, 30, 1992-2003.	1.2	262
45	A phase III randomized, placebo-controlled, double-blind study of niraparib plus abiraterone acetate and prednisone versus abiraterone acetate and prednisone in patients with metastatic prostate cancer (NCT03748641). <i>Annals of Oncology</i> , 2019, 30, v354.	1.2	2
46	Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2019, 5, 1159.	7.1	50
47	Plasma AR status and cabazitaxel in heavily-treated metastatic castration-resistant prostate cancer. <i>European Journal of Cancer</i> , 2019, 116, 158-168.	2.8	29
48	Multimodal Approach to Outcome Prediction in Metastatic Castration-Resistant Prostate Cancer by Integrating Functional Imaging and Plasma DNA Analysis. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	8
49	Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 556-569.	10.7	90
50	Plasma Androgen Receptor Copy Number Status at Emergence of Metastatic Castration-Resistant Prostate Cancer: A Pooled Multicohort Analysis. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	3.0	15
51	Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test. <i>Prostate Cancer and Prostatic Diseases</i> , 2019, 22, 195-205.	3.9	39
52	Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019, 75, 368-373.	1.9	64
53	Plasma DNA Analysis in Prostate Cancer: Opportunities for Improving Clinical Management. <i>Clinical Chemistry</i> , 2019, 65, 100-107.	3.2	16
54	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. <i>Annals of Oncology</i> , 2019, 30, e3.	1.2	16

#	ARTICLE	IF	CITATIONS
55	Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol. <i>Annals of Oncology</i> , 2018, 29, 1235-1248.	1.2	196
56	Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. <i>Nature Genetics</i> , 2018, 50, 682-692.	21.4	182
57	Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. <i>European Urology</i> , 2018, 73, 715-723.	1.9	105
58	Prostate cancers that $\Delta$ Wnt <sup>TM</sup> respond to abiraterone. <i>Annals of Oncology</i> , 2018, 29, 290-292.	1.2	3
59	Plasma DNA and Metastatic Castration-Resistant Prostate Cancer: The Odyssey to a Clinical Biomarker Test. <i>Cancer Discovery</i> , 2018, 8, 392-394.	9.4	7
60	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018, 73, 178-211.	1.9	488
61	Treatment-induced changes in the androgen receptor axis: Liquid biopsies as diagnostic/prognostic tools for prostate cancer. <i>Molecular and Cellular Endocrinology</i> , 2018, 462, 56-63.	3.2	12
62	Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. <i>Journal of Clinical Oncology</i> , 2018, 36, 2639-2646.	1.6	131
63	Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. <i>European Urology Oncology</i> , 2018, 1, 449-458.	5.4	19
64	Overall survival (OS) implications for patients with mCRPC through coverage and adoption of nuclear AR-V7 testing by healthcare systems. <i>Annals of Oncology</i> , 2018, 29, viii296-viii297.	1.2	1
65	Prolonged urinary and bowel symptom control in men with non-metastatic castration-resistant prostate cancer (nmCRPC) treated with enzalutamide: Results from the PROSPER study. <i>Annals of Oncology</i> , 2018, 29, viii278-viii279.	1.2	2
66	Effects of abiraterone acetate plus prednisone/prednisolone in high and low risk metastatic hormone sensitive prostate cancer. <i>Annals of Oncology</i> , 2018, 29, viii722.	1.2	14
67	Plasma androgen receptor and serum chromogranin A in advanced prostate cancer. <i>Scientific Reports</i> , 2018, 8, 15442.	3.3	21
68	Implementing molecular characterisation of prostate cancer tissue from patients recruited to the multi-centre STAMPEDE trial: The STRATOSPHERE consortium. <i>Annals of Oncology</i> , 2018, 29, vi10.	1.2	0
69	Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. <i>Lancet</i> , 2018, 392, 2353-2366.	13.7	901
70	Circulating Tumour DNA in Muscle-Invasive Bladder Cancer. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2568.	4.1	15
71	Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate Cancer. <i>JAMA Oncology</i> , 2018, 4, 1179.	7.1	190
72	An open-label, multicenter, phase Ib study investigating the effect of apalutamide on ventricular repolarization in men with castration-resistant prostate cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2018, 82, 457-468.	2.3	18

#	ARTICLE	IF	CITATIONS
73	Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH) Tj ETQq1 1 06784314 rg5T /Ove	5.4	28
74	Consensus Statement on Circulating Biomarkers for Advanced Prostate Cancer. European Urology Oncology, 2018, 1, 151-159.	1.2	4
75	Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Annals of Oncology, 2017, 28, 1508-1516.	27.0	1,315
76	Precision, complexity and stigma in advanced prostate cancer terminology: it is time to move away from "castration-resistant" prostate cancer. Annals of Oncology, 2017, 28, 1692-1694.	1.2	45
77	Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. New England Journal of Medicine, 2017, 377, 338-351.	1.4	1
78	Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters. Annals of Oncology, 2017, 28, 2472-2480.	1.2	24
79	Upfront Docetaxel in the Post-STAMPEDE World: Lessons from an Early Evaluation of Non-trial Usage in Hormone-Sensitive Prostate Cancer. Clinical Oncology, 2017, 29, e174-e175.	2.5	54
80	Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone. Annals of Oncology, 2017, 28, 90-95.	1.2	0
81	Phenotypic diversity of circulating tumour cells in patients with metastatic castration-resistant prostate cancer. BJU International, 2017, 120, E30-E44.	1.6	54
82	Phase II study of prednisone-dexamethasone switch in metastatic castration resistant prostate cancer (mCRPC) patients treated with abiraterone and prednisone (AA+P). Annals of Oncology, 2017, 28, v276.	1.6	9
83	Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. Journal of Clinical Oncology, 2017, 35, 1530-1541.	1.6	5
84	A phase IV, randomized, double-blind, placebo (PBO)-controlled study of continued enzalutamide (ENZA) post prostate-specific antigen (PSA) progression in men with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC).. Journal of Clinical Oncology, 2017, 35, 5004-5004.	1.6	0
85	Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Update on safety and efficacy.. Journal of Clinical Oncology, 2017, 35, 173-173.	1.6	0
86	Circulating androgen receptor and serum chromogranin A in castration-resistant prostate cancers (CRPC) patients treated with abiraterone and enzalutamide.. Journal of Clinical Oncology, 2017, 35, 160-160.	1.6	0
87	Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status.. Journal of Clinical Oncology, 2017, 35, 5071-5071.	1.6	0
88	Association of androgen receptor (AR) gene status in plasma DNA with outcome on enzalutamide in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC): Exploratory results from the PREMIERE trial" On behalf of SOGUG.. Journal of Clinical Oncology, 2017, 35, 5016-5016.	1.6	1
89	Association of androgen receptor (AR) status in plasma DNA with outcome on enzalutamide (enza) or abiraterone (abi) for castration resistant prostate cancer (CRPC).. Journal of Clinical Oncology, 2017, 35, 5060-5060.	3.8	19
90	Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, 131-141.		

#	ARTICLE	IF	CITATIONS
91	Visualizing whole-body treatment response heterogeneity using multi-parametric magnetic resonance imaging. <i>Journal of Algorithms and Computational Technology</i> , 2016, 10, 290-301.	0.7	15
92	Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses. <i>Clinical Genitourinary Cancer</i> , 2016, 14, 485-493.	1.9	30
93	Diagnostic Gleason score and castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2016, 27, 962-964.	1.2	4
94	Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells. <i>Cancer Research</i> , 2016, 76, 2731-2742.	0.9	79
95	AR aberrations and resistance to abiraterone or enzalutamide. <i>Nature Reviews Urology</i> , 2016, 13, 697-698.	3.8	33
96	Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016, 70, 724-731.	1.9	59
97	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. <i>Lancet, The</i> , 2016, 387, 1163-1177.	13.7	1,570
98	Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer. <i>JAMA Oncology</i> , 2016, 2, 348.	7.1	155
99	Prostate cancer. <i>Lancet, The</i> , 2016, 387, 70-82.	13.7	801
100	A randomized trial of abiraterone acetate (AA) administered with 1 of 4 glucocorticoid (GC) regimens in metastatic castration-resistant prostate cancer (mCRPC) patients (pts).. <i>Journal of Clinical Oncology</i> , 2016, 34, 261-261.	1.6	1
101	Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, 131-141.	3.8	16
102	Circulating <i>AR</i> copy number and outcome to enzalutamide in docetaxel-treated metastatic castration-resistant prostate cancer. <i>Oncotarget</i> , 2016, 7, 37839-37845.	1.8	69
103	PSA levels after dexamethasone withdrawal (DW) in castration resistant prostate cancer (CRPC).. <i>Journal of Clinical Oncology</i> , 2016, 34, 278-278.	1.6	0
104	Loco-regional treatment (LRT) for M1 at diagnosis prostate cancer (PCa) patients (pts) and impact on overall survival (OS): A retrospective analysis.. <i>Journal of Clinical Oncology</i> , 2016, 34, 280-280.	1.6	0
105	Validation of a population pharmacokinetic (PPK) model for onapristone (ONA) in patients (pts) with cancer: Analysis of 2 clinical trials.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14099-e14099.	1.6	0
106	Circulating <i>AR</i> copy number and outcome to enzalutamide in patients with metastatic castration-resistant prostate cancer after docetaxel.. <i>Journal of Clinical Oncology</i> , 2016, 34, e16583-e16583.	1.6	0
107	Clinical and radiological characteristics of metastatic prostate cancer (mPCa) patients (pts) with liver metastases (LM) and association with overall survival (OS).. <i>Journal of Clinical Oncology</i> , 2016, 34, 5043-5043.	1.6	0
108	Integrative Clinical Genomics of Advanced Prostate Cancer. <i>Cell</i> , 2015, 161, 1215-1228.	28.9	2,660

#	ARTICLE	IF	CITATIONS
109	Cabazitaxel—a key therapeutic option in prostate cancer. <i>Nature Reviews Urology</i> , 2015, 12, 312-313.	3.8	3
110	The development of abiraterone acetate for castration-resistant prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 289-294.	1.6	14
111	Sequencing of agents in castration-resistant prostate cancer. <i>Lancet Oncology</i> , The, 2015, 16, e279-e292.	10.7	141
112	PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients. <i>British Journal of Cancer</i> , 2015, 113, 1225-1233.	6.4	76
113	PTEN Protein Loss and Clinical Outcome from Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. <i>European Urology</i> , 2015, 67, 795-802.	1.9	195
114	Improvements in Radiographic Progression-Free Survival Stratified by <i>ERG</i> Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone Acetate. <i>Clinical Cancer Research</i> , 2015, 21, 1621-1627.	7.0	51
115	Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. <i>British Journal of Cancer</i> , 2015, 112, 1166-1174.	6.4	59
116	Progressive computed tomography (CT) appearances preceding malignant spinal cord compression (MSCC) in men with castration-resistant prostate cancer. <i>Clinical Radiology</i> , 2015, 70, 359-365.	1.1	7
117	Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. <i>Annals of Oncology</i> , 2015, 26, 1589-1604.	1.2	279
118	Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration. <i>Clinical Cancer Research</i> , 2015, 21, 4586-4596.	7.0	171
119	Circulating Tumor Cell Biomarker Panel As an Individual-Level Surrogate for Survival in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1348-1355.	1.6	343
120	Targeting extra-gonadal androgens in castration-resistant prostate cancer. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 145, 157-163.	2.5	13
121	Prioritizing precision medicine for prostate cancer. <i>Annals of Oncology</i> , 2015, 26, 1041-1042.	1.2	11
122	Circulating cell-free AR and CYP17A1 copy number variations may associate with outcome of metastatic castration-resistant prostate cancer patients treated with abiraterone. <i>British Journal of Cancer</i> , 2015, 112, 1717-1724.	6.4	112
123	DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2015, 373, 1697-1708.	27.0	1,796
124	Plasma <i>AR</i> and abiraterone-resistant prostate cancer. <i>Science Translational Medicine</i> , 2015, 7, 312re10.	12.4	366
125	Sarcomatoid carcinoma of the prostate: <i>ERG</i> fluorescence <i>in situ</i> hybridization confirms epithelial origin. <i>Histopathology</i> , 2015, 66, 898-901.	2.9	26
126	Phase I Study of Nintedanib Incorporating Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Patients With Advanced Solid Tumors. <i>Oncologist</i> , 2015, 20, 368-369.	3.7	5



#	ARTICLE	IF	CITATIONS
127	Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. <i>Oncogene</i> , 2015, 34, 1745-1757.	5.9	147
128	Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. <i>Cancer</i> , 2014, 120, 3346-3352.	4.1	128
129	Reply: "Comment on Anti-tumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer". <i>British Journal of Cancer</i> , 2014, 110, 267-268.	6.4	1
130	Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2014, 25, 657-662.	1.2	94
131	Validation and utilisation of high-coverage next-generation sequencing to deliver the pharmacological audit trail. <i>British Journal of Cancer</i> , 2014, 111, 828-836.	6.4	34
132	Tumor clone dynamics in lethal prostate cancer. <i>Science Translational Medicine</i> , 2014, 6, 254ra125.	12.4	298
133	Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial. <i>European Urology</i> , 2014, 66, 799-802.	1.9	56
134	Reply to: Enzalutamide after failure of docetaxel and abiraterone in metastatic castrate resistant prostate cancer. <i>European Journal of Cancer</i> , 2014, 50, 1042-1043.	2.8	0
135	External Validation of a Prognostic Model Predicting Overall Survival in Metastatic Castrate-resistant Prostate Cancer Patients Treated with Abiraterone. <i>European Urology</i> , 2014, 66, 8-11.	1.9	21
136	Visceral Disease in Castration-resistant Prostate Cancer. <i>European Urology</i> , 2014, 65, 270-273.	1.9	172
137	Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. <i>European Journal of Cancer</i> , 2014, 50, 78-84.	2.8	178
138	Preclinical Evaluation of Imaging Biomarkers for Prostate Cancer Bone Metastasis and Response to Cabozantinib. <i>Journal of the National Cancer Institute</i> , 2014, 106, dju033.	6.3	59
139	Evolution of androgen receptor targeted therapy for advanced prostate cancer. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 365-376.	27.6	172
140	Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. <i>British Journal of Cancer</i> , 2014, 111, 2248-2253.	6.4	52
141	Anti-androgen monotherapy for metastatic prostate cancer. <i>Lancet Oncology</i> , The, 2014, 15, 543-544.	10.7	20
142	Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents. <i>European Urology</i> , 2014, 66, 459-465.	1.9	128
143	Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). <i>Annals of Oncology</i> , 2013, 24, 1807-1812.	1.2	310
144	A step toward functionally characterized prostate cancer molecular subtypes. <i>Nature Medicine</i> , 2013, 19, 966-967.	30.7	5

#	ARTICLE	IF	CITATIONS
145	Identifying prognostic signatures in the blood of ovarian cancer patients. <i>Gynecologic Oncology</i> , 2013, 128, 1-2.	1.4	6
146	Improved Survival in a Cohort of Trial Participants with Metastatic Castration-resistant Prostate Cancer Demonstrates the Need for Updated Prognostic Nomograms. <i>European Urology</i> , 2013, 64, 300-306.	1.9	85
147	Strategies for managing ACTH dependent mineralocorticoid excess induced by abiraterone. <i>Cancer Treatment Reviews</i> , 2013, 39, 966-973.	7.7	37
148	Novel Strategies to Test Biological Hypotheses in Early Drug Development for Advanced Prostate Cancer. <i>Clinical Chemistry</i> , 2013, 59, 75-84.	3.2	11
149	Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer. <i>Annals of Oncology</i> , 2013, 24, 1416-1418.	1.2	62
150	New horizons for prostate cancer: part 2. <i>Trends in Urology &amp; Men's Health</i> , 2013, 4, 13-16.	0.4	0
151	New horizons for prostate cancer: part 1. <i>Trends in Urology &amp; Men's Health</i> , 2013, 4, 38-40.	0.4	0
152	First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2013, 109, 2579-2586.	6.4	78
153	Antitumour activity of abiraterone and diethylstilboestrol when administered sequentially to men with castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2013, 109, 1079-1084.	6.4	18
154	Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. <i>British Journal of Cancer</i> , 2013, 109, 325-331.	6.4	34
155	Molecular Pathways: Inhibiting Steroid Biosynthesis in Prostate Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 3353-3359.	7.0	80
156	Circulating Tumor Cells Count and Morphological Features in Breast, Colorectal and Prostate Cancer. <i>PLoS ONE</i> , 2013, 8, e67148.	2.5	82
157	Improved Therapeutic Targeting of the Androgen Receptor: Rational Drug Design Improves Survival in Castration-Resistant Prostate Cancer. <i>Current Drug Targets</i> , 2013, 14, 408-419.	2.1	13
158	Clinical and Biochemical Consequences of CYP17A1 Inhibition with Abiraterone Given with and without Exogenous Glucocorticoids in Castrate Men with Advanced Prostate Cancer. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2012, 97, 507-516.	3.6	234
159	Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?. <i>Annals of Oncology</i> , 2012, 23, 2943-2947.	1.2	224
160	Novel, gross chromosomal alterations involving PTEN cooperate with allelic loss in prostate cancer. <i>Modern Pathology</i> , 2012, 25, 902-910.	5.5	48
161	Redefining the therapeutic landscape for CRPC. <i>Nature Reviews Urology</i> , 2012, 9, 63-64.	3.8	16
162	Prognostic value of blood mRNA expression signatures in castration-resistant prostate cancer: a prospective, two-stage study. <i>Lancet Oncology</i> , The, 2012, 13, 1114-1124.	10.7	125

#	ARTICLE	IF	CITATIONS
163	Interactions of Abiraterone, Eplerenone, and Prednisolone with Wild-type and Mutant Androgen Receptor: A Rationale for Increasing Abiraterone Exposure or Combining with MDV3100. <i>Cancer Research</i> , 2012, 72, 2176-2182.	0.9	240
164	The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1609-1617.	4.1	82
165	Derivation and Validation of Blood mRNA Expression Signatures to Stratify Castration Resistant Prostate Cancer Patients and Predict Poor Outcome. <i>Annals of Oncology</i> , 2012, 23, ix15.	1.2	0
166	Abiraterone in Patients with Metastatic Castration-Resistant Prostate Cancer Progressing after Docetaxel and MDV3100: A Multicentre Study. <i>Annals of Oncology</i> , 2012, 23, ix304-ix305.	1.2	2
167	Advances in the management of high-risk localised and metastatic prostate cancer. <i>BJU International</i> , 2012, 109, 8-13.	2.5	11
168	Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer. <i>Molecular and Cellular Endocrinology</i> , 2012, 360, 68-75.	3.2	29
169	Multi-Purpose Utility of Circulating Plasma DNA Testing in Patients with Advanced Cancers. <i>PLoS ONE</i> , 2012, 7, e47020.	2.5	136
170	Improved Survival in Patients with Metastatic Castration Resistant Prostate Cancer (MCRPC) Treated on Clinical Trials. <i>Annals of Oncology</i> , 2012, 23, ix298.	1.2	0
171	New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway. <i>Clinical Cancer Research</i> , 2011, 17, 1649-1657.	7.0	177
172	Utilizing circulating tumor cells: challenges and pitfalls. <i>Current Opinion in Genetics and Development</i> , 2011, 21, 50-58.	3.3	101
173	The Role of Abiraterone Acetate in the Management of Prostate Cancer: A Critical Analysis of the Literature. <i>European Urology</i> , 2011, 60, 270-278.	1.9	53
174	Beyond Hormone Therapy for Prostate Cancer with PARP inhibitors. <i>Cancer Cell</i> , 2011, 19, 573-574.	16.8	15
175	Baseline Circulating Tumor Cell Counts Significantly Enhance a Prognostic Score for Patients Participating in Phase I Oncology Trials. <i>Clinical Cancer Research</i> , 2011, 17, 5188-5196.	7.0	29
176	The CT flare response of metastatic bone disease in prostate cancer. <i>Acta Radiologica</i> , 2011, 52, 557-561.	1.1	55
177	Novel biomarker approaches for improving therapeutic strategies in metastatic breast cancer. , 2011, , 165-181.		0
178	Reporting the Capture Efficiency of a Filter-Based Microdevice: A CTC Is Not a CTC Unless It Is CD45 Negative Letter: Figure 1.. <i>Clinical Cancer Research</i> , 2011, 17, 3048-3049.	7.0	18
179	Translating Scientific Advancement into Clinical Benefit for Castration-Resistant Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 3867-3875.	7.0	53
180	Unbiased and Automated Identification of a Circulating Tumour Cell Definition That Associates with Overall Survival. <i>PLoS ONE</i> , 2011, 6, e27419.	2.5	42

#	ARTICLE	IF	CITATIONS
181	Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer. <i>British Journal of Cancer</i> , 2010, 102, 678-684.	6.4	234
182	Significant and Sustained Antitumor Activity in Post-Docetaxel, Castration-Resistant Prostate Cancer With the CYP17 Inhibitor Abiraterone Acetate. <i>Journal of Clinical Oncology</i> , 2010, 28, 1489-1495.	1.6	370
183	All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer. <i>Annals of Oncology</i> , 2010, 21, 1851-1857.	1.2	179
184	Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). <i>Annals of Oncology</i> , 2010, 21, 109-113.	1.2	157
185	Abiraterone Acetate Is Well Tolerated Without Concomitant Use of Corticosteroids. <i>Journal of Clinical Oncology</i> , 2010, 28, e560-e561.	1.6	33
186	Studies of <i>TMPRSS2-ERG</i> Gene Fusions in Diagnostic Trans-Rectal Prostate Biopsies. <i>Clinical Cancer Research</i> , 2010, 16, 1340-1340.	7.0	17
187	The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2010, 13, 117-125.	3.9	5
188	Antitumor Activity with CYP17 Blockade Indicates That Castration-Resistant Prostate Cancer Frequently Remains Hormone Driven. <i>Cancer Research</i> , 2009, 69, 4937-4940.	0.9	152
189	Selective Inhibition of CYP17 With Abiraterone Acetate Is Highly Active in the Treatment of Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 3742-3748.	1.6	545
190	Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. <i>Annals of Oncology</i> , 2009, 20, 27-33.	1.2	216
191	PSA as an intermediate end point in clinical trials. <i>Nature Reviews Urology</i> , 2009, 6, 473-475.	3.8	10
192	Hormone-sensitive prostate cancer: a case of ETS gene fusion heterogeneity. <i>Journal of Clinical Pathology</i> , 2009, 62, 373-376.	2.0	21
193	A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2009, 15, 4978-4985.	7.0	31
194	Steroid Hormone Receptors in Prostate Cancer: A Hard Habit to Break?. <i>Cancer Cell</i> , 2009, 16, 458-462.	16.8	203
195	A novel, spontaneously immortalized, human prostate cancer cell line, Bob, offers a unique model for pre-clinical prostate cancer studies. <i>Prostate</i> , 2009, 69, 1507-1520.	2.3	9
196	Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement. <i>British Journal of Cancer</i> , 2009, 101, 1137-1144.	6.4	62
197	Integration of <i>ERG</i> gene mapping and gene expression profiling identifies distinct categories of human prostate cancer. <i>BJU International</i> , 2009, 103, 1256-1269.	2.5	54
198	Characterization of <i>ERG</i> , <i>AR</i> and <i>PTEN</i> Gene Status in Circulating Tumor Cells from Patients with Castration-Resistant Prostate Cancer. <i>Cancer Research</i> , 2009, 69, 2912-2918.	0.9	518

#	ARTICLE	IF	CITATIONS
199	Expression profiling of CD133 <sup>+</sup> and CD133 <sup>+</sup> epithelial cells from human prostate. <i>Prostate</i> , 2008, 68, 1007-1024.	2.3	64
200	Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. <i>Oncogene</i> , 2008, 27, 253-263.	5.9	400
201	Complex patterns of ETS gene alteration arise during cancer development in the human prostate. <i>Oncogene</i> , 2008, 27, 1993-2003.	5.9	133
202	Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. <i>British Journal of Cancer</i> , 2008, 99, 314-320.	6.4	98
203	Targeting CYP17: established and novel approaches in prostate cancer. <i>Current Opinion in Pharmacology</i> , 2008, 8, 449-457.	3.5	87
204	CYP17 inhibition as a hormonal strategy for prostate cancer. <i>Nature Reviews Urology</i> , 2008, 5, 610-620.	1.4	96
205	Dissecting prostate carcinogenesis through ETS gene rearrangement studies: implications for anticancer drug development. <i>Journal of Clinical Pathology</i> , 2008, 61, 891-896.	2.0	12
206	Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven. <i>Journal of Clinical Oncology</i> , 2008, 26, 4563-4571.	1.6	819
207	A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours. <i>British Journal of Cancer</i> , 2007, 97, 1338-1343.	6.4	65
208	Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 257-262.	1.6	127
209	Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor. <i>Clinical Cancer Research</i> , 2007, 13, 3611-3616.	7.0	185
210	Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2007, 13, 6187-6194.	7.0	226
211	Circulating tumor cells expressing the insulin growth factor-1 receptor (IGF-1R): Method of detection, incidence and potential applications. <i>Journal of Clinical Oncology</i> , 2007, 25, 3507-3507.	1.6	0
212	Management Strategies for Hormone-Refractory Prostate Cancer. <i>American Journal of Cancer</i> , 2006, 5, 163-169.	0.4	0
213	Update on tubulin-binding agents. <i>Pathologie Et Biologie</i> , 2006, 54, 72-84.	2.2	134
214	A phase I study of intravenous TZT-1027 administered on day 1 and day 8 of a three-weekly cycle in combination with carboplatin given on day 1 alone in patients with advanced solid tumours. <i>Annals of Oncology</i> , 2006, 17, 1313-1319.	1.2	21
215	Improving the outcome of patients with castration-resistant prostate cancer through rational drug development. <i>British Journal of Cancer</i> , 2006, 95, 767-774.	6.4	72
216	A phase I study of BIBF 1120, an orally active triple angiokinase inhibitor (VEGFR, PDGFR, FGFR) given continuously to patients with advanced solid tumours, incorporating dynamic contrast enhanced magnetic resonance imaging (DCE-MRI). <i>Journal of Clinical Oncology</i> , 2006, 24, 3015-3015.	1.6	14

#	ARTICLE	IF	CITATIONS
217	A phase 1 dose finding study of CHR-2797, an inhibitor of M1 aminopeptidases, in patients with advanced solid tumours. <i>Journal of Clinical Oncology</i> , 2006, 24, 3053-3053.	1.6	0
218	Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. <i>BJU International</i> , 2005, 96, 1241-1246.	2.5	186
219	Prostate epithelial stem cells. <i>Cell Proliferation</i> , 2005, 38, 363-374.	5.3	99
220	Making sense of antisense. <i>European Journal of Cancer</i> , 2005, 41, 2812-2818.	2.8	43